Sven Kruspe, Cindy Meyer, Ulrich Hahn 

Slides:



Advertisements
Similar presentations
Guido Tomás Rozenblum, Tomás Kaufman, Alfredo Daniel Vitullo 
Advertisements

Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Targeting Multidrug-resistant Staphylococci with an anti-rpoA Peptide Nucleic Acid Conjugated to the HIV-1 TAT Cell Penetrating Peptide  Mostafa FN Abushahba,
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Léa L Lesueur, Lluis M Mir, Franck M André 
Oligonucleotide Delivery to the Lung: Waiting to Inhale
Volume 18, Issue 2, Pages (February 2010)
Volume 19, Issue 2, Pages (February 2011)
Molecular Therapy - Nucleic Acids
Dual Role of Act1 in Keratinocyte Differentiation and Host Defense: TRAF3IP2 Silencing Alters Keratinocyte Differentiation and Inhibits IL-17 Responses 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 4, Issue 1, Pages (July 2001)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 22, Issue 1, Pages (January 2014)
Volume 22, Issue 1, Pages (January 2014)
Molecular Therapy - Nucleic Acids
Zihua Zeng, Ching-Hsuan Tung, Youli Zu 
Targeting Insulin Receptor with a Novel Internalizing Aptamer
Volume 25, Issue 1, Pages 5-7 (January 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Oncolytics
Haiyan Dong, Ji Ma, Jie Wang, Zai-Sheng Wu, Patrick J Sinko, Lee Jia 
Jan Hoinka, Phuong Dao, Teresa M Przytycka 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Léa L Lesueur, Lluis M Mir, Franck M André 
Molecular Therapy - Nucleic Acids
Neurotensin receptor–1 and –3 complex modulates the cellular signaling of neurotensin in the HT29 cell line  Stéphane Martin, Valérie Navarro, Jean Pierre.
Volume 19, Issue 12, Pages (December 2011)
Molecular Therapy - Nucleic Acids
Volume 23, Issue 12, Pages (December 2015)
Molecular Therapy  Volume 7, Issue 5, (May 2003) DOI: /S (16)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Gene Silencing Mediated by siRNA-binding Fusion Proteins Is Attenuated by Double- stranded RNA-binding Domain Structure  James C Geoghegan, Brian L Gilmore,
Wei-Yun Lai, Bo-Tsang Huang, Jen-Wei Wang, Pei-Ying Lin, Pan-Chyr Yang 
Molecular Therapy - Nucleic Acids
Modular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8+ T-cell Activation Against Tumors  Benjamin J Umlauf, Chin-Ying.
Yu-Ying He, Jian-Li Huang, Michelle L. Block, Jau-Shyong Hong, Colin F
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)
Normal Human Merkel Cells are Present in Epidermal Cell Populations Isolated and Cultured from Glabrous and Hairy Skin Sites  Julie Fradette, Danielle.
Molecular Therapy - Nucleic Acids
In Vivo Tracking of Mesechymal Stem Cells Using Fluorescent Nanoparticles in an Osteochondral Repair Model  Jong Min Lee, Byung-Soo Kim, Haeshin Lee,
Volume 18, Issue 3, Pages (March 2010)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Molecular Therapy - Nucleic Acids
Volume 25, Issue 10, Pages (October 2017)
Molecular Therapy - Nucleic Acids
Jia Liu, Thomas Gaj, Mark C Wallen, Carlos F Barbas 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Figure 1. Effects of Gal-4 on apoptosis and proliferation of monocytes
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 21, Issue 4, Pages (April 2013)
CD28 Aptamers as Powerful Immune Response Modulators
Volume 10, Issue 6, Pages (December 2004)
Volume 18, Issue 2, Pages (February 2010)
Presentation transcript:

Chlorin e6 Conjugated Interleukin-6 Receptor Aptamers Selectively Kill Target Cells Upon Irradiation  Sven Kruspe, Cindy Meyer, Ulrich Hahn  Molecular Therapy - Nucleic Acids  Volume 3, (January 2014) DOI: 10.1038/mtna.2013.70 Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Detection of chlorin e6 in BaF3/gp130/IL6R/TNF cells. Cells were incubated three times with chlorin e6 derivatized aptamer (AIR-3A-ce6, 50 nmol/l) for 45 minutes in media without serum. Between these, incubations cells were cultivated in media containing serum for 5 hours each. Internalization was analyzed via flow cytometry for cells treated with (a) AIR-3A-ce6, (b) free chlorin e6, (c) shuffled-AIR-3A-ce6, (d) and hIL-6R- cells as control. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Retention of chlorin e6 derivatized aptamer AIR-3A (AIR-3A-ce6) in BaF3/gp130/IL6R/TNF cells. Cells were incubated with 50 nmol/l AIR-3A-ce6 or free ce6 for 45 minutes in medium without serum or with 1 µmol/l free ce6 over night. Afterwards, the cells were cultivated in serum containing medium. The retention of chlorin e6 was determined via flow cytometry. The values represent median cell fluorecence intensities ± SD. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 BaF3/gp130/IL6R/TNF cells after internalization of chlorin e6 derivatized aptamer, AIR-3A-ce6. Cells were incubated with 50 nmol/l AIR-3A-ce6 for 45 minutes in medium without serum. Accumulation of the internalized AIR-3A-ce6 was analyzed via confocal laser scanning microscopy (chlorin e6) and white light micrograph (light) confirming broad chlorin e6 distribution in the cytosol. (a–c) 50 nmol/l AIR-3A-ce6, 45 minutes incubation; (d–f) free ce6, 50 nmol/l, 45 minutes incubation; (g–i) over night incubation with 1 µmol/l free ce6; scalebar = 10 µm. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Vitality of BaF3/gp130/IL6R/TNF cells after treatment with chlorin e6 derivatized aptamer, AIR-3A-ce6. Cells were incubated with 150 nmol/l AIR-3A-ce6 conjugate for 25 minutes in phosphate-buffered saline containing 0.5% bovine serum albumin. Cells subjected to two incubations were rested for 3 hours between the incubations. Subsequently, the cells were irradiated (660 nm, 100 J/cm2; 30 mW/cm2) or kept in the dark. Error bars represent mean ± SD of two independently repeated experiments with one exposition (grey) or two subsequent expositions (shaded) to the aptamer-ce6 conjugate. Cell vitality values are given in reference to the control cells. Asterisks indicate significance P < 0.01. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Vitality of BaF3/gp130/IL6R/TNF cells after treatment with free chlorin e6. Cells were incubated with ce6 over night, washed and cultivated in drug-free medium. Subsequently, the cells were irradiated (660 nm, 100 J/cm2; 30 mW/cm2) or kept in the dark. The cell viability was determined usind annexin pi double staining. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Structure of chlorin e6. Molecular Therapy - Nucleic Acids 2014 3, DOI: (10.1038/mtna.2013.70) Copyright © 2014 The American Society of Gene & Cell Therapy Terms and Conditions